-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35

Benzinga·06/02/2026 17:00:11
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $33 to $35.